Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine

Exclusion Criteria

• •The following classes of patients will be excluded:
• •1. Patients with unstable psychiatric status defined as having a total score on BPRS of 50 or higher
• •2. Patients who have suicidal or homicidal ideation, intent, or plan or viewed as having a significant risk of suicidal or violent behavior;
• •3. Patients with cognitive impairment as defined by a score of 24 or less on the MMSE
• •4. Patients with current diagnosis of alcohol or substance use disorder made according to DSM-5 criteria
• •5. Patients with clinically significant unstable medical condition defined as follows: a comorbid abnormal movement disorder more prominent than tardive dyskinesia (e.g., parkinsonism, akathisia, truncal dystonia), a score of greater than 2 on two or more items of the Simpson-Angus Scale, or a history of neuroleptic malignant syndrome.
• •6. Patients previously treated with Valbenazine or any other medication specifically indicated for tardive dyskinesia
• •7. Patients currently taking strong CYP3A4 inducers, dopamine agonists, MAO inhibitors, stimulants, and/or VMAT2 inhibitors
• •8. Patients with congenital long QT syndrome or arrhythmias associated with prolonged QT interval
• •9. Patients with risk factors for prolonged QT such as electrolyte abnormalities (hypokalemia, hypocalcemia, hypomagnesemia), anorexia nervosa, diuretic use, certain heart conditions, and other medical conditions
• •10. Patients tested positive for Coronavirus Covid-19
• •11. Patients with impaired decision-making capacity
• •12. Institutionalized individuals
• •13. Prisoners